Stockscreener 앱 받기
18.66
5.78%
1.02
시장 영업 전:
18.91
0.25
+1.34%
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - Yahoo Finance
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX) - The Globe and Mail
DFTX: Phase III data for DT120 in GAD and MDD expected in 2024, targeting major unmet needs - TradingView
DFTX: Three pivotal data readouts for GAD and MDD expected in 2024, with strong Phase II results - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Definium Therapeutics stock hits 52-week high at 18.71 USD - Investing.com Australia
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighHere's Why - MarketBeat
Definium Therapeutics Announces New Employee Inducement Grants - National Today
New Definium hires receive stock options and performance shares - Stock Titan
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (2026-03-09) - Seeking Alpha
How Definium’s Widening 2025 Loss Will Impact Definium Therapeutics (DFTX) Investors - simplywall.st
Royce & Associates LP Invests $955,000 in Definium Therapeutics, Inc. $DFTX - MarketBeat
Equities Analysts Set Expectations for DFTX Q1 Earnings - Defense World
Q1 EPS Forecast for Definium Therapeutics Cut by Analyst - MarketBeat
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX) - The Globe and Mail
A Look At Definium Therapeutics (DFTX) Valuation As Wider Full Year Loss Refocuses Investor Expectations - simplywall.st
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - simplywall.st
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH) - The Globe and Mail
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates - Business Wire
Psychedelic Therapeutics & Drug Development Conference kicks off in New Orleans - Mugglehead Magazine
1.20%
0.06%
자본화:
|
볼륨(24시간):